Cardiology

Mehrdad Ghoreishi, MD explores the latest advances in aortic disease treatment and the role of minimally invasive techniques.

Olpasiran sustained reductions in oxidized phospholipids on apoB in patients with ASCVD and elevated Lp(a) levels in the Phase 2 dose-ranging trial.

Cardiovascular hospitalization rates were higher in the US than in Denmark, driven by a significant increase in heart failure and myocardial infarction hospitalizations.

Announced by LIB Therapeutics Inc., the agency has set a PDUFA target action date of December 12, 2025.

Use of medications for secondary CVD prevention is low globally, and in most country income-level groups, with no indication of improvement.

SGLT2 inhibitors lower the risk of MACE in older age, despite smaller HbA1c reductions, while GLP-1 RAs were more cardioprotective in younger individuals with T2D.

A new tool may enable earlier identification of heart failure, potentially reducing hospitalizations and premature death.

New research tested how specialized hypertennsion medical curriculum impacted residents’ treatment of hypertensive urgency in the outpatient setting.

A survey suggests ablation leads to improved sports performance in athletes with atrial fibrillation.

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

A study found propranolol significantly lowers ischemic stroke risk in women with migraine, highlighting its potential for stroke prevention in high-risk groups.

Lipid screening after bulk orders and outreach letters increased significantly at 3 months, but supplemental text messaging had no further impact.

The January 2025 cardiology month in review highlights new NDA acceptances, clearance of the first Lp(a) test in molar units, and national trends in preventive aspirin use.

A study indicated that telomere length may not directly cause age-related brain diseases, but healthier lifestyles could counteract the harmful effects of shorter telomeres.

Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

Merck announced robust efficacy data on the benefit of sotatercept for PAH in the STELLAR and ZENITH studies led to a loss of clinical equipoise in HYPERION.

Results from the Phase 3 LIBerate-HoFH trial found LDL-C responses generally similar between patients treated with lerodalcibep and evolocumab.

Awarded to Roche, the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay will be the first 510(k) cleared test measuring Lp(a) in nanomoles per liter (nmol/L).

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

The regulatory agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, 2025.

Enobosarm led to a statistically significant benefit in the protection of lean mass in patients with overweight or obesity receiving semaglutide.

Medicaid-insured heart transplant recipients reported worse survival and higher risk of cardiac allograft vasculopathy over 5 years.

Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.